Les équipes



Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N. Breast cancer-derived TGF-β and TNF-α compromise IFN-α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer. 2013 Feb 7.

 El Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY. Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Target Oncol. 2013 Jan 25.


Bachelard-Cascales E, Chapellier M, Delay E and Maguer-Satta V. A protocol to quantify Mammary Early Common Progenitors from long-term mammosphere culture. Current protocols in Stem Cells Biology. Chapter 1:Unit 1E.7, 2012.

Bertrand J, Despeaux M, Joly S, Bourogaa E, Gallay N, Demur C, Bonnevialle P, Louache F, Maguer-Satta V, Vergnolle N, Payrastre B and Racaud-Sultan C. Sex differences in the GSK3-mediated survival of adherent leukemic progenitors. Oncogene. 31:694-705, 2012. doi: 10.1038/onc.2011.258.

Caux C. and Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Targeted Oncol.  7:1-2, 2012.

Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting Pattern Recognition Receptors in cancer immunotherapy. Targeted Oncol. 7:29-54, 2012.

Labidi-Galy S.I., Treilleux I., Goddard-Léon S., Combes J.D., Blay J.Y., Ray-Coquard I., Caux C., and Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology, 1(3):379-81, 2012.

Manuel M, Tredan O, Bachelot T, Clapissson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY and Ménétrier-Caux C. Lymphopenia Combined with low TCR Diversity (divpenia) predicts poor Overall Survival in Metastatic Breast Cancer Patient. OncoImmunology, 1(4):433-42, 2012.

Marabelle A,Caux C. Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. Blood. 2012 Nov 29;120(23):4454-5. doi: 10.1182/blood-2012-09-455105.

Ménétrier-Caux C, Faget J, Biota C, Gobert M, Blay JY and Caux C. Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. OncoImmunology, 1(5):759-61, 2012.

Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C and Zou W. Targeting regulatory T cells. Targeted Oncol. 7:15-28, 2012.

Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S and Puisieux A. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. Plos Genetics. 8(5): e1002723, 2012.

Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Ménétrier-Caux C, Blay JY CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 2012.

Ray-Coquard I, Chauvin F., Leblanc E.  Caux C., Hoarau H., Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F. Le PAIR-gynécologie : recherche multi/interdisciplinaire en cancérologie gynécologique. Les problèmes à résoudre en 2012. Bull Cancer. 99(4):479-498, 2012.

Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-Dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C. Patients with metastatic breast cancer leading to CD4(+) T cell lymphopaenia have poor outcome. Eur J Cancer. 2012 Dec 19.

Segura E., Valladeau-Guilemond J., Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 209:653-60, 2012.


Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, Tredan O, Goddard-Leon S, Pin JJ, Mignotte H, Barthelemy-Dubois C, Caux C, Lebecque S, Blay JY. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer. 11:213-23, 2011.

Maguer-Satta V, Chapellier M, Delay E and Bachelard-Cascales E. CD10: a tool to crack the role of stem cells in breast cancer. PNAS 108(49): author reply E1265, 2011.

Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon FX, Dumontet C, Puisieux A, Nicolini F and Maguer-Satta V.  Deregulation of TWIST-1 as a novel prognostic factor in chronic myeloid leukemia. Blood 117:1673-6, 2011.

de Brito C, Tomkowiak M, Ghittoni R, Caux C, Leverrier Y, Marvel J. CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic dells. J Immunol. 186:1503-11, 2011.

Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 17:700-7, 2011.

Faget J., Biota C., Bachelot T., Gobert M., Treilleux I., Goutagny N., Durand I., Léon-Goddard S.,  Blay J.Y., Caux C. and Ménétrier-Caux C. Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells. Cancer Res. 71:6143-52, 2011.

Gougelet A, Perez J, Pissaloux D, Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY, Alberti L. miRNA Profiling: How to Bypass the Current  Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma. 2011:1-14, 2011.

Hayette S., Chabane K., Michallet M., Michallat E., Cony-Makhoul P., Salesse  S., Maguer-Sattta V, Magaud JP and Nicolini FE. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res. 35:38-43, 2011.

Joha S., Dauphin V, Leprêtre F., Corm S., Nicolini, F., Roumier C., Nibourel, O., Grardel N., Maguer-Satta V, Idziorek T., Figeac M., Laï JL., Quesnel B., Etienne G., Guilhot F., Lippert E., Preudhomme C., and Roche-Lestienne C. Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leuk Res. 35:448-58, 2011.

Labidi-Galy SI, Ray-Coquard I, Sisirak V, Treilleux I, Meeus P, Mithieux F, Bajard A, Combes JD, Gobert M, Faget J, Guastalla JP, Tredan O, Ménétrier-Caux C, Caux C, Blay JY and Bendriss-Vermare N.Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 171:5423-34, 2011.

Labidi-Galy S.I., Faget J., Treilleux I., Ménétrier-Caux C., Caux C., and Bendriss-Vermare N. Immunologie du cancer de l’ovaire : de la théorie à la thérapeutique. "Cancer de l’ovaire" Edition 2, (Edition : Springer), chapter book, pp 613-626, 2011.

Maguer-Satta V, Besançon R and Bachelard-Cascales E. Neutral endopeptidase (NEP/CD10): a multifaceted environment actor in stem cells, physiological mechanisms and cancer. Stem Cells, 29:389-96, 2011.

Maguer-Satta V.  The stem cell niche: the black master of cancer. “Cancer Stem Cells Theories and Practice” (édition: Stanley Shostak), chapter book p1-26, 2011.

Perez J., Bardin C., Rigal C., Besse A., Rousseau R., and Dutour A. Anti MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 31(9):2813-20, 2011.

Ruptier C, De Gaspéris A, Ansieau S, Granjon A, Tanière P, Lafosse I, Shi H, Petitjean A, Taranchon-Clermont E, Tribollet V, Voeltzel T, Scoazec JY, Maguer-Satta V, Puisieux A, Hainaut P, Cavard C, Caron de Fromentel C. TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression. Oncogene. Nov 17;30(46):4656-65, 2011.

Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B,  Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, and Bendriss-Vermare N. CCR6/CCR10-mediated plasmacytoid dendritic cells recruitment to inflamed epithelia following instruction in lymphoid organs. Blood. 118(19):5130-40, 2011.

BREVET: Antibodies directed against ICOS and uses thereof. Filed May 2011, n° EP11305385.5. Inventors: JULIEN FAGET, MÉNÉTRIER-CAUX CHRISTINE, JACQUES NUNES, DANIEL OLIVE, CAUX CHRISTOPHE


Bachelard-Cascales, E.. Chapellier, M. Delay, E. Pochon, G. Voeltzel, T. Puisieux, A. Caron de Fromentel C and Maguer-Satta. V. The CD10-enzyme is a key player to identify and regulate Human mammary stem cells. Stem Cells 28,1081-88, 2010. 

Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchère D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. Jul;16(7):781-7, 2010.

Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Ray-Coquard I, Cupissol D, Chevreau C, Perol D, Goncalves A, Jimenez M, Bringuier PP, Blay JY. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer. Aug 10;103(4):482-5, 2010. 

Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 129: 680-90, 2010.

Goutagny N, Jiang Z, Tian J, Parroche P, Schlicki J, Monks BM, Ulbrandt N, Ji H, Kiener P, Coyle AJ, and Fitzgerald KA.Cell Type-Specific Recognition of Human Metapneumoviruses (HMPVs) by Retinoic Acid-Inducible Gene I (RIG-I) and TLR7 and Viral Interference of RIG-I Ligand Recognition by HMPV-B1 Phosphoprotein. J Immunol. 184(3):1168-79, 2010.

Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D. Impaired TLR7 and TLR9 signaling: from chronic viral infections to cancer. Trends Imumnol, 31(10):391-7, 2010.

Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Pérol D, Blay JY; for the French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. Sep 21, 2010. 

Perrot I, Garrone P, Deauvieau F, Massacrier C, Brière F, Morel Y, Paturel C, Caux C. TLR3 on mDC and RIG-I on NK cells engagement by dsRNA are required for optimal innate immune cell activation. J Immunol 185(4):2080-8, 2010

Zannetti C, Bonnay F, Takeshita F, Ménétrier-Caux C, Tommasino M, Hasan U. C/EBPδ and STAT-1 are required for TLR8 transcriptional activiy. J Biol chem. 285(45):34773-80, 2010


Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S, Bourquin C, Goutagny N, Jiang Z, Fitzgerald KA, Rothenfusser S, Endres S, Hartmann G and Hornung V. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes, J.Immunol. 182: 6824-33, 2009. 

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY and Menetrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, Cancer Res., 69: 2000-9, 2009. 

Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, ssels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. Aug 0;27(24):3969-74, 2009. 

Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, Flament C, Emile JF, Le Cesne A and Zitvogel L. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients, Cancer Res., 69: 3563-9, 2009.

Ménétrier-Caux C, Gobert M and Caux C. Differences in tumor regulatory T cell localization and activation status impact patients’ outcome. Cancer Res. 69:2595-8, 2009. 

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. Jul 1;69(13):5383-91, 2009. 

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol. Jul 1;27(19):3126-32, 2009. 

BREVET: TCR diversity allow to identify high risk patient relapsing from breast cancer eligible for innovative therapy. Filed December 2009, PCT/FR2010/00829. Inventors: MANUEL MANUARII, MENETRIER-CAUX CHRISTINE, BACHELOT THOMAS, BLAY JEAN-YVES, PACUAL NICOLAS, CAUX CHRISTOPHE


Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C and Puisieux A. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence, Cancer Cell, 14: 79-89, 2008. 

Fayolle C, Pourchet J, de Fromentel CC, Puisieux A, Doré JF, Voeltzel T. Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol. Jan;128(1):196-202, 2008.

Fitamant J, Guenebeaud C, Guix C, Coissieux MM, Scoazec JY, Bachelot T, Bernet A and Mehlen P. Netrin-1 dictates breast tumor metastasis by inhibiting apoptosis. PNAS, 105:4850-5, 2008. 

Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan HA, Pool J, Wilschut J, Fitzgerald KA and Huckriede A. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling, PLoS.Pathog., 4: e1000138, 2008. 

Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat, P, Fournier C, aieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. J Clin Oncol. Nov 10;26(32):5269-74, 2008. 

Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Theou-Anton N, Lemoine A, Blay JY and Emile JF. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin.Cancer Res. 14: 2285-94, 2008.


Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. Mar 20;25(9):1107-13, 2007. 

Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Briere J, Ferme C and Salles G. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte, J.Clin.Oncol., 25: 1732-40, 2007.

Hasan UA, Caux C, Perrot I, Doffin AC, Menetrier-Caux C, Trinchieri G, Tommasino M and Vlach J. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs, Proc.Natl.Acad.Sci.U.S.A, 104: 8047-52, 2007. 

Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, Young HA, Ching LM and Vogel SN. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis, J.Exp.Med., 204: 1559-69, 2007.


Bechetoille N, Andre V, Valladeau J, Perrier E and Dezutter-Dambuyant C. Mixed Langerhans cell and interstitial/dermal dendritic cell subsets emanating from monocytes in Th2-mediated inflammatory conditions respond differently to proinflammatory stimuli, J.Leukoc.Biol., 80: 45-58, 2006. 

Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van RN, Caux C, Ait-Yahia S, Vicari A, Kaiserlian D and Dubois B. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo, Immunity. 24: 191-201, 2006. 

Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak V, Berthier-Vergnes O, de Saint-Vis B, Caux C, Dezutter-Dambuyant C, Lebecque S and Valladeau J. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria, J.Immunol., 177: 7959-67, 2006.


Alberti L., T. Bachelot, C. Biota, JY Blay. A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor. Cancer Res. 2005; 65: 2-5. 2005

Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-LafayI, Ginestet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin JC, Cordier JF and Carrie C. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis, J.Clin.Oncol., 23: 8748-56, 2005. 

de Bouteiller, O., E. Merck, U. A. Hasan, S. Hubac, B. Benguigui, G. Trinchieri, E. E. Bates, and C. Caux. 2005. Recognition of double stranded RNA by human toll like receptor 3 and downstream receptor signaling requires multimerisation and an acidic pH. J.Biol.Chem. 280:38133-45;2005 

Dubois B and Caux C. Critical role of ITIM-bearing FcgammaR on DCs in the capture and presentation of native antigen to B cells, Immunity. 23: 463-4, 2005. 

Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, Trinchieri G, Caux C and Garrone P. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells, J.Exp.Med. 201: 1435-46, 2005.